All In Biotech

Drug Trial Radar · NCT04266301

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 530 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

530

Actual

Start

Jun 8, 2020

Primary completion

Oct 2, 2024

Study completion Oct 2, 2024

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 12, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase III multi-center, randomized, two-arm parallel-group, double-blind, placebo-controlled study of MBG453 or placebo added to azacitidine in adult participants with intermediate, high or very high-risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who are not eligible for intensive chemotherapy or hematopoietic stem cell transplantation (HSCT) according to medical judgment by the investigator. The purpose of the current study was to assess clinical effects of MBG453 in combination with azacytidine in adult participants with IPSS-R intermediate, high, very high risk MDS and CMML-2.

Conditions

  • Myelodysplastic Syndromes
  • Leukemia, Myelomonocytic, Chronic

Interventions

  • SabatolimabDrug

    A dose of MBG453 800 mg was administered intravenously (IV) every 4 weeks (Q4W).

  • AzacitidineDrug

    A dose of Azacitidine 75 mg/m2 was administered IV or subcutaneously (SC) on Day 1-7, or Day 1-5, 8 and 9.

  • PlaceboDrug

    A dose of placebo 800 mg was administered intravenously every 4 weeks (Q4W).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) (Primary Efficacy Results)Time frame: up to approx. 39 months
  2. Overall Survival (OS) (Final Efficacy Results)Time frame: up to approx. 52 months

Locations

149 sites in 36 countries. Site status is shown where the registry gives one.

  • Yuma Regional Cancer Center

    Yuma, Arizona

  • University of California LA

    Los Angeles, California

  • Yale University School Of Medicine

    New Haven, Connecticut

  • Mayo Clinic Jacksonville

    Jacksonville, Florida

  • University Of Miami

    Miami, Florida

  • Northwestern University

    Chicago, Illinois

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Hackensack University Medical Ctr

    Hackensack, New Jersey

  • Weill Cornell Medicine NY-Presb

    New York, New York

  • University of Rochester Medical Ctr

    Rochester, New York

  • University of Virginia

    Charlottesville, Virginia

  • Novartis Investigative Site

    Pilar, Buenos Aires, Argentina

  • Novartis Investigative Site

    Wooloongabba, Queensland, Australia

  • Novartis Investigative Site

    Clayton, Victoria, Australia

  • Novartis Investigative Site

    Perth, Western Australia, Australia

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Innsbruck, Tyrol, Austria

  • Novartis Investigative Site

    Brasschaat, Belgium

  • Novartis Investigative Site

    Roeselare, West-Vlaanderen, Belgium

  • Novartis Investigative Site

    Florianópolis, Santa Catarina, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Calgary, Alberta, Canada

  • Novartis Investigative Site

    Toronto, Ontario, Canada

  • Novartis Investigative Site

    Viña del Mar, Valparaiso, Chile

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Beijing, China

  • Novartis Investigative Site

    Jinan, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Shanghai, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Tianjin, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Guangzhou, Guangdong, China

  • Novartis Investigative Site

    Shenzhen, Guangdong, China

  • Novartis Investigative Site

    Wuhan, Hubei, China

  • Novartis Investigative Site

    Wuhan, Hubei, China

  • Novartis Investigative Site

    Suzhou, Jiangsu, China

  • Novartis Investigative Site

    Changchun, Jilin, China

Showing 40 of 149 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.